Chief investigator Professor Alan Burnett, from Cardiff Universitys School of Medicine, commented on the findings:
These promising results demonstrate how targeting a protein present in more than 90 per cent of AML patients can boost treatment without excessively increasing side effects.
Although there has been some controversy around the use of GO following its withdrawal in the US two years ago, these results appear extremely promising and suggest no such cause for concern if the appropriate dose is given. Crucially, this represents some of the first progress in treating AML patients of this age group for at least 20 years.
More top news
This week daytime temperatures reached 19C. Next week we are expecting 13C by day and close to freezing at night.
Mainly dry and bright but a cold easterly wind developing
Police have released CCTV images in the search for missing Katie Grout, from Berwick.